Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Scinai Immunotherapeutics Ltd. (SCNI) Market Cap & Valuation Ratios

Scinai Immunotherapeutics Ltd. (SCNI) has a market cap of $3.2M and a price-to-sales ratio of 2.2, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

SCNIScinai Immunotherapeutics Ltd.Follow SCNI — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
3.2M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
—

Peers

biotechnology · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
SCNI0.0—0.6——+30%—-102%
NKTX0.1——————-50%
AVXL0.1———————
HUMA0.1—36.5——+159%——
VYGR0.1————-19%-340%-74%
LENZ0.1—3.5————-75%
HRTX0.1—1.0——+1.0%-7%-8%
ALDX0.0———————
EYPT0.0————-95%—-275%
IRLA0.0———————
ATYR0.0————-19%—-142%
Median of these 10—3.5——-19%-174%-74%

; EV/Sales 0.6 vs. 3.5.

Growth vs. price

each dot a company · hover or tap for values

Scinai Immunotherapeutics Ltd. — questions

What is Scinai Immunotherapeutics Ltd.'s market cap?
$3.2M.
What is Scinai Immunotherapeutics Ltd.'s price-to-sales ratio?
2.2.

Every figure on this page comes from Scinai Immunotherapeutics Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.